Pulmonary Arterial Hypertension (PAH) Market
Pulmonary Arterial Hypertension (PAH) Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Pulmonary Arterial Hypertension (PAH) Market Size and Growth
The Pulmonary Arterial Hypertension (PAH) market research reports indicate a growing demand for treatment options due to increasing prevalence of the disease. The market size for PAH is estimated to be valued at $5.3 billion, with a projected CAGR of 5.8% over the next five years. The market is expected to witness significant growth due to rising awareness and advancements in treatment options.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Actelion
◍ Gilead Sciences
◍ United Therapeutics
◍ GlaxoSmithKline
◍ Pfizer
◍ Bayer
◍ Arena
Competitive Landscape: Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer, Arena are leading players in the PAH market offering innovative treatments. These companies invest in R&D, strategic partnerships, and marketing to grow the market. Sales revenue for some companies: Actelion ($2.14 billion), Gilead Sciences ($22.45 billion), United Therapeutics ($1.3 billion).
Request Sample Report
Market Segmentation
By Application
Hospital
Clinic
Request Sample Report
By Product
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
Market Growth
Request Sample Report
$ X Billion USD
